Filter By Category
Archives
Share on -
DUSIGITUMAB
Generic Name: DUSIGITUMAB
ABSTRACT -
Dusigitumab is an investigational monoclonal antibody designed to neutralize insulin-like growth factors IGF-1 and IGF-2, thereby reducing activation of IGF signaling in tumors.
DOSAGE -
No approved dosage. Intravenous oncology trial dosing is protocol-specific.
SIDE EEFECTS -
- Fatigue
- Nausea
- Hyperglycemia or metabolic changes
- Infusion reactions
- Laboratory abnormalities
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Infusion hypersensitivity
- Rash or urticaria
- Angioedema
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- Antidiabetic therapy may need monitoring if glucose changes occur
- Other anticancer drugs may increase overlapping toxicity
- Immunosuppressants may modify biologic response
PREAUTONS–
- Monitor glucose and metabolic parameters
- Use only in clinical-trial settings
- Monitor infusion reactions and organ function
WARNINGS –
- Investigational agent; safety and efficacy not established
- Serious hypersensitivity reactions are possible
Share on -
. Developed by